News

Hind Rectifiers Q2 Results

NCC Q2 Results

STL Q2 Results

Net Profit At ₹4 Cr Vs Loss Of ₹14 Cr (YoY)

Revenue down 4% At ₹1,034 Cr Vs ₹1,074 Cr (YoY)

EBITDA up 10.3% At ₹129 Cr Vs ₹117 Cr (YoY)

Margin At 12.5% Vs 10.9% (YoY)

JBM Auto Q2 Results

Net Profit down 44.2% At Rs 25 Cr Vs Rs 44.8 Cr (YoY)

Revenue up 11.2% At Rs 315.2 Cr Vs Rs 283.4 Cr (YoY)

EBITDA up 8.5% At Rs 41 Cr Vs Rs 37.8 Cr (YoY)

Margin At 13% Vs 13.3% (YoY)

Net Profit Flat At Rs 90 Cr (YoY)

Revenue up 4% At Rs 1,342.5 Cr Vs Rs 1,292.4 Cr (YoY)

EBITDA up 3.3% At Rs 194.5 Cr Vs Rs 188 Cr (YoY)

Margin Flat At 14.5% (YoY)

Abbott India Ltd on Thursday (November 6) reported a 16% year-on-year rise in net profit to ₹415.3 crore for the quarter ended September 2025, compared with ₹359 crore in the same period last year, driven by steady revenue growth and stronger operating margins.

Revenue from operations grew 7.7% to ₹1,757 crore, up from ₹1,633 crore a year earlier, the company said in its exchange filing. The healthcare major’s EBITDA rose 14.5% to ₹502.6 crore from ₹439 crore in the corresponding quarter last year. Operating performance improved, with EBITDA margin expanding to 28.6%, compared with 26.9% in the same quarter last year.

here

Shares of Cholamandalam Investment & Finance Company fell as much as 5% on Thursday, November 6, in response to its September quarter results.

Cholamandalam’s asset quality deteriorated on a sequential basis with gross NPA at 4.57% from 4.29% in June, while Net NPA also deteriorated to 3.07% to 2.86% in the previous quarter. These figures are as per the RBI asset classification norms. Provision Coverage Ratio (PCR) for the quarter stood at 33.88% from 34.41% in June.

here

Net Profit up 13.9% At Rs 84.6 Cr Vs Rs 74.3 Cr (YoY)

Revenue up 19% At Rs 1,535 Cr Vs Rs 1,290 Cr (YoY)

EBITDA up 21.4% At Rs 177.9 Cr Vs Rs 146.5 Cr (YoY)

Margin At 11.6% Vs 11.4% (YoY)

Net Profit At Rs 553 Crore Vs Loss Of Rs 443 Crore (YoY)

One-Time Gain At Rs 142 Crore Vs Loss Of Rs 8 Crore (YoY)

Revenue Up 8.4% At 12019 Crore Vs 11 090 Crore (YoY)

EBITDA Up 40% At 2,205 Crore Vs 1,575 Crore (YoY)

Margin At 18.3% Vs 14.2% (YoY)

UPL Raises FY26 EBITDA Guidance To 12-16% Vs Earlier 10-14%

Revenue Growth Guidance Unchanged, Growth Seen At 4-8%

Net Profit up 23.8% At Rs 21.8 Cr Vs Rs 17.6 Cr (YoY)

Revenue down 3.1% At Rs 278.6 Cr Vs Rs 287.5 Cr (YoY)

EBITDA up 26.1% At Rs 39 Cr Vs Rs 30.95 Cr (YoY)

Margin At 14% Vs 10.8% (YoY)

Zydus Lifesciences Ltd on Tuesday reported a robust second-quarter performance for FY26, with consolidated net profit rising 39% year-on-year to ₹1,259 crore, compared with ₹911 crore in the same period last year.

The growth was supported by healthy business momentum across geographies and a sharp rise in forex gains.

The company recorded a foreign exchange gain of ₹414 crore, compared with ₹45 crore in the previous year.

here

Chola Invst Q2

Net Profit At Rs 1,155 Cr Vs CNBC-TV18 Poll Of Rs 1,170 Cr

NII At Rs 3,378 Cr Vs CNBC-TV18 Poll Of Rs 3,359 Cr

PPoP At Rs 2,458 Cr Vs CNBC-TV18 Poll Of Rs 2,482 Cr

Provisions At Rs 897 Cr Vs CNBC-TV18 Poll Of Rs 907 Cr

Net Profit up 20%  At Rs 1,155 Cr Vs Rs 963 Cr (YoY)

NII up 24.5%  At Rs 3,378 Cr Vs Rs 2,713 Cr (YoY)

Gross NPA At 5.57% Vs 4.29% (QoQ)

Board Approves Stock Split In The Ratio Of 1:5

Net Profit down 14%  At Rs 30.4 Cr Vs Rs 35.3 Cr (YoY)

Revenue up 10%  At Rs 219 Cr Vs Rs 199 Cr (YoY)

EBITDA down 2.5%  At Rs 58 Cr Vs Rs 59.4 Cr (YoY)

Margin At 26.4% Vs 29.8% (YoY)

Net Profit down 5.6% At Rs 55.4 Cr Vs Rs 58.7 Cr (YoY)

Revenue up 2.8%  At Rs 244.6 Cr Vs Rs 238 Cr (YoY)

EBITDA down 2.8%  At Rs 87.1 Cr Vs Rs 89.5 Cr (YoY)

Margin At 35.60% Vs 37.62% (YoY)

Net Profit up 2.7% At Rs 33.4 Cr Vs Rs 32.5 Cr (YoY)

Revenue up 17.8%  At Rs 968 Cr Vs Rs 822 Cr (YoY)

EBITDA up 10.3%  At Rs 85.60 Cr Vs Rs 77.60 Cr (YoY)

Margin At 8.84% Vs 9.44% (YoY)

Net profit (GU)16% at ₹415.3 crore vs ₹359 crore (YoY)

Revenue (GU)7.7% at ₹1,757 crore vs ₹1,633 crore (YoY)

EBITDA (GU)14.5% at ₹502.6 crore vs ₹439 crore (YoY)

Margin at 28.6% vs 26.9% (YoY)

Net loss at ₹64.4 crore vs loss of ₹54.2 crore (YoY)

Revenue (RD)12% at ₹494.8 crore vs ₹562.6 crore (YoY)

EBITDA (RD)7% at ₹14.8 crore vs ₹16 crore (YoY)

Margin at 3% vs 2.8% (YoY)

Net profit (GU)38% at ₹1,259 crore vs ₹911 crore (YoY)

Revenue (GU)17% at ₹6,123 crore vs ₹5,237 crore (YoY)

EBITDA (GU)38% at ₹2,014 crore vs ₹ 1,462 crore (YoY)

Margin at 32.9% vs 27.9% (YoY)

Forex gain at ₹414 crore vs gain of ₹45 crore (YoY)

Shares of Indoco Remedies Ltd. gained on Thursday, November 6, after the company witnessed a slight improvement in earnings in the second quarter.

The company’s net loss improved to ₹8 crore from ₹9.6 crore in the September quarter last year.

here

Shares of Symphony Ltd. fell as much as 7% on Thursday, November 6, in response to its results for the September quarter, which were lower on a year-on-year basis across parameters.

The company’s net profit fell 66% from last year to ₹19 crore. The company had reported a net profit of ₹56 crore during the same quarter last year.

here

The company’s net loss at the end of the September quarter narrowed to ₹418 crore from a net loss of ₹495 crore it reported during the same quarter last year. Estimates from Kotak Institutional Equities had pegged the loss to narrow further to ₹346 crore.

It has also cut its revenue and margin guidance for the full year.

here

Net Loss At Rs 21.8 Cr Vs Profit Of Rs 0.02 Cr (YoY)

Revenue up 12.7% At Rs 1,376.7 Cr Vs Rs 1,222 Cr (YoY)

EBITDA down 1.8% At Rs 192 Cr Vs Rs 196 Cr (YoY)

Margin At 14% Vs 16% (YoY)

Sun Pharma To CNBC-TV18:

Business Has Been Consistently Growing Over The Past Few Years

Focusing On Brands In India

Continue To Focus On Therapies Which The Company Has Identified

Expect To Grow Better Than The Industry

Expect Traction To Continue Going Forward

Expect Innovative Medicine Biz To Grow In The Mid-teens

Expect R&D Spend To Be At Near 6% For FY26

The stock is curretly down 7.3%.

Symphony Q2:

Net Profit down 66% At Rs 19 Cr Vs Rs 56 Cr (YoY)

Revenue down 44% At Rs 163 Cr Vs Rs 289 Cr (YoY)

EBITDA down 69% At Rs 24 Cr Vs Rs 77 Cr (YoY)

Margin At 15% Vs 26.6 (YoY)

Shares of Blue Star fell over 6% on Thursday, November 6, after the management cut its full year revenue growth guidance to flat from the earlier projection of 5%.

The management during its earnings call highlighted that the festive season has not gone well despite the reduction in the GST rates for the consumer durables like Room Air-Conditioners.

here

– Booking Value Up 64% YoY & 20% QoQ To ₹8,505 Crore

– Achieved 48% Of Annual Guidance For Booking Value In H1FY26

– Remains On Track To Beat Guidance Of ₹32,500 Crore Booking Value For FY26

– Collections Up 2% YoY & 11% QoQ  To ₹4,066 Crore

– Area Sold Up 39% YoY & 16% QoQ At 7.14 million square feet

Net Profit Up 21% At 405 Vs Rs 335 Crore

Revenue Down 32% At 740 Crore 1093 Crore

EBITDA Loss At Rs 513 Crore Vs EBITDA Of Rs 32 Crore

FY26 revenue growth target cut to flat Vs earlier target of 5% growth

Upper end growth target of UCP segment cut, now seen at 7-7.5%

Blue Star Says | From Concall:

Q2 Was A Tough Qtr, Unseasonal Rains & Delay In GST Cut Impacted Performance

Believe H2 Will Be Better Than H1, But Doubt It Will Make Up For The Loss

FY26 Will Likely See A Flat Growth On A YoY Basis

RAC Industry Likely To See Decline Of 15% YoY This Year

Saw More Than Of 35% Sales From Sep 22 Till Diwali

Tariff Related Uncertainties Still Persist

There Is No Doubt About Long-term Growth Prospects Of Co

Fundamentals Continue To Remain Strong, Growth Momentum ContinuesNewsLive TVMarketPopular CategoriesCalculatorsTrending NowLet's Connect with CNBCTV 18Network 18 Group :©TV18 Broadcast Limited. All rights reserved.